Roger M. Nitsch MD

Roger M. Nitsch, M.D. is a Full Professor at the Faculty of Medicine, University of Zurich, and Director at the Institute of Regenerative Medicine (IREM), University of Zurich Campus Schlieren. He also servers as Director at the Hospital for Psychogeriatric Medicine at the Psychiatric University Hospital Zurich. A neuroscientist with a background in medicine, Roger M. Nitsch is recognized as a pioneer of disease-modifying therapeutic approaches for neurodegenerative diseases with more than 30 years of experience in Alzheimer’s disease research. His main research focus is the immunotherapy of neurodegenerative diseases. He spearheaded the development of Aducanumab, a human antibody for the treatment and prevention of Alzheimer’s disease.

Prior to his position at the University of Zurich, Switzerland, Roger M. Nitsch held research positions at M.I.T. (Cambridge, MA) and MGH / Harvard Medical School (Boston, MA), and was a Group Leader at the Center for Molecular Neurobiology at University of Hamburg, Germany. He was a fellow at the Max-Planck-Institute for Medical Research in Heidelberg, Germany, received an M.D. from University of Heidelberg Medical School followed by Habilitation in Neurobiochemistry at University of Heidelberg, Germany.